Is Humana Stock Outperforming the Dow?
Humana expects 25% Medicare Advantage membership growth by 2026, plans to exit unprofitable markets. Stock outperforms Dow but lags rivals like Centene. Analysts give 'Moderate Buy' rating, $421.35 mean price target, 4.5% upside.
How this was made
The 30-second read
Why it matters
The 25% membership growth guidance and market exits provide a fresh data point for valuation models.
Market read
New guidance may influence analyst expectations and short-term price movement.
What to watch
Potential regulatory changes to Medicare Advantage could affect growth assumptions.
Background
Humana is a major U.S. health insurer with a focus on Medicare Advantage plans.
Ticker impact
Humana reiterated 2026 Medicare Advantage membership growth of ~25% and announced exit from less profitable markets affecting 600k members.
Potential 4-6% upside over the next weeks if guidance is absorbed.
Analyst consensus rating is Moderate Buy with price targets indicating limited upside; new guidance adds fresh data.
Market effects
Medicare Advantage sector may see reallocation as Humana trims low-margin markets.
U.S. health insurance market sentiment modestly positive.
Limited to U.S. healthcare investors.
Counterpoint
The exit from markets could signal deeper profitability issues, limiting upside.
Key entities
- CompanyHumana Inc.
U.S. health insurer providing Medicare Advantage.
